% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • bs572 bs572 Mar 20, 2013 6:44 PM Flag

    Declining cash flow.

    Valuation depends on cash flow and pipeline. Currently the later has little value only because SPPI has no proven track record of resurrecting fallen angels.which they buy from other Pharmas.

    The run up to +$17 was based on Fusilev sales . IMO that chapter is now over and the stock is likeley to revert to its pre Fusilev valuations closer to the $5 level.

    Many will consider that level is too low and they may be right. Good luck.!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.97-0.120(-1.97%)Apr 17 4:00 PMEDT